Rhythm Pharmaceuticals, Inc.
RYTM
Rang in aandelen
#2937
Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company with commercial... Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company with commercial products, dedicated to the discovery, development, and market launch of therapies addressing rare genetic conditions that cause obesity. Its leading pharmaceutical, IMCIVREE, functions as a powerful agonist of the melanocortin-4 receptor (MC4R). This medication is indicated for treating obesity stemming from deficiencies in pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or the leptin receptor (LEPR), alongside its use in patients with Bardet-Biedl and Alström syndromes. Furthermore, the company is progressing setmelanotide (the active compound in IMCIVREE) through Phase II clinical trials. These studies are evaluating its potential for a broader spectrum of applications, including obesity caused by heterozygous POMC or LEPR deficiencies, steroid receptor coactivator 1 (SRC1) deficiency, SH2B1 deficiency, MC4 receptor deficiency, and obesity associated with Smith-Magenis syndrome, POMC epigenetic disorders, and other MC4R-related conditions. Rhythm Pharmaceuticals holds a collaborative research agreement with the Clinical Registry Investigating Bardet-Biedl Syndrome. The firm, headquartered in Boston, Massachusetts, was established in 2008 and changed its name from Rhythm Metabolic, Inc. to Rhythm Pharmaceuticals, Inc. in October 2015.
Aandeelprijs
$89.83
Marktkapitalisatie
$6.18B
Verandering (1 dag)
1.81%
Verandering (1 jaar)
-20.07%
Land
US
Handel Rhythm Pharmaceuticals, Inc. (RYTM)
Categorie
Healthcare
Aandelsplitsingen voor Rhythm Pharmaceuticals, Inc. (RYTM)
Het aandeel Rhythm Pharmaceuticals, Inc. (symbool: RYTM) heeft in totaal 0 splitsingen ondergaan.
De meest recente splitsing vond plaats op Oct 20, 2026.
Eén aandeel RYTM dat vóór Oct 20, 2026 werd gekocht, staat nu gelijk aan 0 aandelen RYTM.
De meest recente splitsing vond plaats op Oct 20, 2026.
Eén aandeel RYTM dat vóór Oct 20, 2026 werd gekocht, staat nu gelijk aan 0 aandelen RYTM.
Lijst van aandelen splitsingen
| Jaar | Splitsing | Vermenigvuldiging | Cumulatieve vermenigvuldiging |
|---|---|---|---|
| Niet genoeg gegevens voor de verstrekte datums. | |||
Aandelsplitsingen van vergelijkbare bedrijven of concurrenten
| Bedrijf | Aantal aandelen splitsingen | Cumulatieve vermenigvuldiging | Land |
|---|---|---|---|
| 1 | x2 |
US
|
|
| 0 | - |
US
|
|
| 1 | x3 |
AU
|
|
| 0 | - |
CH
|
|
| 0 | - |
NL
|
